Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis.

Chronic inflammation triggers the aberrant expression of a DNA mutator enzyme, activation-induced cytidine deaminase (AID), and contributes to tumorigenesis through the accumulation of genetic aberrations. To gain further insight into the inflammation-mediated genotoxic events required for carcinogenesis, we examined the role of chronic inflammation in the emergence of genetic aberrations in the liver with constitutive AID expression. Treatment with thioacetamide (TAA) at low-dose concentrations caused minimal hepatic inflammation in both wild-type (WT) and AID transgenic (Tg) mice. None of the WT mice with low-dose TAA administration or AID Tg mice without hepatic inflammation developed cancers in their liver tissues over the 6 month study period. In contrast, all the AID Tg mice with TAA treatment developed multiple macroscopic hepatocellular carcinomas during the same observation period. Whole exome sequencing and additional deep-sequencing analyses revealed the enhanced accumulation of somatic mutations in various genes, including dual specificity phosphatase 6 (Dusp6), early growth response 1 (Egr1) and inhibitor of DNA binding 2 (Id2), which are putative tumor suppressors, in AID-expressing liver with TAA-mediated hepatic inflammation. Microarray and quantitative reverse transcription-polymerase chain reaction analyses showed the transcriptional upregulation of various genes including Dusp6, Egr1 and Id2 under hepatic inflammatory conditions. Together, these findings suggest that inflammation-mediated transcriptional upregulation of target genes, including putative tumor suppressor genes, enhances the opportunity for inflamed cells to acquire somatic mutations and contributes to the acceleration of tumorigenesis in the inflamed liver tissues.

[1]  K. Kinoshita,et al.  Expression of activation‐induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis , 2007, International journal of cancer.

[2]  T. Ushijima,et al.  Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. , 2012, Gastroenterology.

[3]  J. de Vellis,et al.  Tumor necrosis factor‐α regulation of the Id gene family in astrocytes and microglia during CNS inflammatory injury , 1999, Glia.

[4]  T. Honjo,et al.  Molecular mechanism of class switch recombination: linkage with somatic hypermutation. , 2002, Annual review of immunology.

[5]  T. Oyama,et al.  Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma. , 2011, Carcinogenesis.

[6]  N. Kakazu,et al.  Constitutive Expression of AID Leads to Tumorigenesis , 2003, The Journal of experimental medicine.

[7]  A. Bhagwat,et al.  Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. , 2003, Nucleic acids research.

[8]  Y. Matsumoto,et al.  Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. , 2014, Gastroenterology.

[9]  Tsutomu Chiba,et al.  Expression of APOBEC2 is transcriptionally regulated by NF‐κB in human hepatocytes , 2006, FEBS letters.

[10]  T. Honjo,et al.  Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. , 2008, Gastroenterology.

[11]  Xin Meng,et al.  TNF-α induces early growth response gene-1 expression via ERK1/2 activation in endothelial cells , 2013, Acta Diabetologica.

[12]  Rebecca C Fitzgerald,et al.  Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis , 2014, Nature Genetics.

[13]  N. Iizuka,et al.  Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile. , 2006, International Journal of Oncology.

[14]  S. Conticello.  The AID/APOBEC family of nucleic acid mutators , 2008, Genome Biology.

[15]  Haiyang Xie,et al.  Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1‐mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma , 2014, Hepatology.

[16]  D. Schatz,et al.  Multiple Transcription Factor Binding Sites Predict AID Targeting in Non-Ig Genes , 2013, The Journal of Immunology.

[17]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[18]  I. Rogozin,et al.  Cutting Edge: DGYW/WRCH Is a Better Predictor of Mutability at G:C Bases in Ig Hypermutation Than the Widely Accepted RGYW/WRCY Motif and Probably Reflects a Two-Step Activation-Induced Cytidine Deaminase-Triggered Process , 2004, The Journal of Immunology.

[19]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[20]  S. Friedman,et al.  Experimental models of hepatocellular carcinoma. , 2008, Journal of hepatology.

[21]  Y. Jan,et al.  Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. , 2003, Carcinogenesis.

[22]  T. Honjo,et al.  Expression of activation-induced cytidine deaminase in human hepatocytes via NF-κB signaling , 2007, Oncogene.

[23]  R. Takahashi,et al.  Parkin as a tumor suppressor gene for hepatocellular carcinoma , 2008, Oncogene.

[24]  K. Kinoshita,et al.  Activation‐induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma , 2008, Hepatology.

[25]  John N Weinstein,et al.  The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. , 2005, Cancer research.

[26]  Jianzhi Zhang,et al.  Genomic evidence for elevated mutation rates in highly expressed genes , 2012, EMBO reports.

[27]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[28]  F. Sato,et al.  Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing , 2011, PloS one.

[29]  E. Hatano,et al.  Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. , 2014, Gastroenterology.

[30]  N. Shepherd,et al.  Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. , 2009, Gastroenterology.

[31]  T. Honjo,et al.  Organ‐specific profiles of genetic changes in cancers caused by activation‐induced cytidine deaminase expression , 2008, International journal of cancer.

[32]  G. Tsujimoto,et al.  Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation , 2012, Oncogene.

[33]  A. Iavarone,et al.  Id family of helix-loop-helix proteins in cancer , 2005, Nature Reviews Cancer.

[34]  T. Furukawa,et al.  Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas , 2005, Modern Pathology.

[35]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[36]  M. Kudo,et al.  p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. , 2013, Cancer research.

[37]  S. Keyse,et al.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases , 2007, Oncogene.

[38]  H. Marusawa,et al.  Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing , 2012, PloS one.

[39]  A. Zeiher,et al.  Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway , 2000, Molecular and Cellular Biology.

[40]  M. Nussenzweig,et al.  Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand , 2003, Nature Immunology.

[41]  Takeshi Azuma,et al.  Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium , 2007, Nature Medicine.

[42]  Y. Matsumoto,et al.  A model of liver carcinogenesis originating from hepatic progenitor cells with accumulation of genetic alterations , 2014, International journal of cancer.

[43]  A. Bhagwat,et al.  Transcription-induced mutations: increase in C to T mutations in the nontranscribed strand during transcription in Escherichia coli. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[45]  T. Honjo,et al.  AID Enzyme-Induced Hypermutation in an Actively Transcribed Gene in Fibroblasts , 2002, Science.

[46]  D. Mercola,et al.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin , 2006, Cancer Gene Therapy.

[47]  X. Castells,et al.  Modelling mutational landscapes of human cancers in vitro , 2014, Scientific Reports.

[48]  F. Alt,et al.  Class-switch recombination: interplay of transcription, DNA deamination and DNA repair , 2004, Nature Reviews Immunology.

[49]  James E. Bradner,et al.  Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic Instability , 2014, Cell.

[50]  Ming-Yao Wu,et al.  Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. , 2002, World journal of gastroenterology.